

Product Datasheet

ARV-766

Catalog No. **BP-02047** · CAS **2750830-09-0** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-11**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PROTACs; Androgen Receptor	Research area Cancer
---	--------------------------------

Molecular formula **C₄₅H₅₄N₇O₆**

Molecular weight **807.9520**

STRUCTURE



DESCRIPTION

ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.

BIOLOGICAL ACTIVITY

Luxdegaltamide (0.03-30 μM, 48 h) induces the expression of CYP3A4 and CYP2C8 mRNA instead of CYP1A2, 2B6, and 2C9 mRNA, with little effect on cytochrome P450 (CYP) and transporter mediated drug interactions (DDI). Luxdegaltamide exhibits anti-tumor activity in mouse LNCaP and VCaP xenograft models.

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1]. Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)[J]. 2023.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.